On March 26, 2024, Novo Integrated Sciences, Inc. (NASDAQ: NVOS), headquartered in Bellevue, Washington, announced several key updates regarding its financial and acquisition activities. The company reported that it has made four additional $25,000 deposits between January and March 2024 to a Court Appointed Receiver to maintain exclusivity for the acquisition of the Ophir Collection, as per the agreement dated November 21, 2023. Furthermore, Novo Integrated Sciences is in compliance with the terms and conditions of a Share Purchase Agreement and a 15-year unsecured Promissory Note with RC Consulting Consortium Group LLC and is awaiting the Buyer's approval for the initial drawdown of funds. Additionally, the company is actively pursuing the monetization of a partial assignment of a $1 Billion Dollar Gold-Bullion backed Bond with international facility providers. These updates were disclosed in a press release attached as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC.

On March 26, 2024, Novo Integrated Sciences, Inc. (NASDAQ: NVOS), headquartered in Bellevue, Washington, announced several key updates regarding its financial and acquisition activities. The company reported that it has made four additional $25,000 deposits between January and March 2024 to a Court Appointed Receiver to maintain exclusivity for the acquisition of the Ophir Collection, as per the agreement dated November 21, 2023. Furthermore, Novo Integrated Sciences is in compliance with the terms and conditions of a Share Purchase Agreement and a 15-year unsecured Promissory Note with RC Consulting Consortium Group LLC and is awaiting the Buyer's approval for the initial drawdown of funds. Additionally, the company is actively pursuing the monetization of a partial assignment of a $1 Billion Dollar Gold-Bullion backed Bond with international facility providers. These updates were disclosed in a press release attached as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC.